Business
PRTC To Showcase Deupirfenidone at ATS Conference
PureTech Health plc announced that its deupirfenidone (LYT-100) program, being advanced by its Founded Entity Celea Therapeutics, will be showcased at the American Thoracic Society International Conference. Presentations will highlight the SURPASS-IPF Phase 3 trial, a head-to-head superiority study comparing deupirfenidone against pirfenidone, aiming to establish deupirfenidone as a new standard of care for idiopathic pulmonary fibrosis (IPF). The company also noted that deupirfenidone has demonstrated potential to stabilize lung function decline with a favorable safety profile in the Phase 2b ELEVATE IPF trial, and that approximately 25% of IPF patients in the U.S. had received treatment as of 2019, indicating a significant unmet need. Disclaimer*
About this update from Puretech Health Plc
13 May 2026 PureTech Health plc PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference Presentations to highlight differentiated approach to advancing deupirfenidone, reinforcing its potential to serve as a new standard of care within the evolving idiopathic pulmonary fibrosis treatment landscape PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced presentations showcasing its deupirfenidone (LYT-100) program at the upcoming American Thoracic Society (ATS) International Conference, taking place in Orlando, Florida, from May 15-20, 2026. Deupirfenidone is an investigational therapy being advanced by PureTech's Founded Entity, Celea Therapeutics (Celea), as a potential new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF). "The SURPASS-IPF program reflects a broader shift in how the field is beginning to think about IPF treatment," said Toby Maher, MD, PhD, Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles, who will present details around the SURPASS-IPF Phase 3 trial. "Historically, clinicians and patients have often accepted modest efficacy because therapeutic options were limited. What makes the Phase 3 SURPASS-IPF trial particularly compelling is not only the head-to-head superiority design against a standard of care, but also the strength and consistency of the underlying dataset supporting it. The previously completed Phase 2b ELEVATE IPF trial included an active comparator arm (pirfenidone) that provided important clinical context, while the Qureight analyses further demonstrate that the enrolled population was highly representative of a well-characterized real-world IPF population. Collectively, these elements increase confidence as the program advances into Phase 3 and support the broader hypothesis that greater preservation of lung function may be achievable in IPF." Presentations include: Industry Program Title: Raising the Bar with SURPASS-IPF: The First Phase 3 Head-to-Head Superiority Trial in IPF Testing Deupirfenidone vs. Pirfenidone Presenter: Toby Maher, MD, PhD Date &am...
View stock analysis, news, and events for Puretech Health Plc